DCF — ASPIRUS IRON RIVER HOPSITAL & CLINIC
Enterprise Value: $-65.4M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-65.4M
Enterprise Value
$-20.5M
PV of Cash Flows
$-44.9M
PV of Terminal Value
$-72.3M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $35.5M | $-4.2M | -12.0% | $-5.7M | $-5.2M |
| Year 2 | $36.6M | $-3.9M | -11.0% | $-5.5M | $-4.5M |
| Year 3 | $37.7M | $-3.7M | -10.0% | $-5.3M | $-4.0M |
| Year 4 | $38.8M | $-3.6M | -9.0% | $-5.2M | $-3.6M |
| Year 5 | $39.9M | $-3.6M | -9.0% | $-5.3M | $-3.3M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-65.4M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$34.5M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.12259033382511181
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5